Kondremul Plain (mineral oil) dosing, indications, interactions, adverse effects, and more

Sections

Sections mineral oil
Dosing & Uses
Interactions
Adverse Effects
Warnings
Pregnancy
Pharmacology
Images
Patient Handout

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

liquid

100%

Constipation

15-45 mL/day PO, single or divided doses

Kondremul: 30-75 mL/day

Dosage Forms & Strengths

liquid

100%

Constipation

<6 years

15-30 mL/year of age; not to exceed 240 mL/day

6-12 years

5-15 mL/day divided qDay, single or divided doses
Kondremul: 10-25 mL/day

>12 years

15-45 mL/day PO, single or divided doses
Kondremul: 30-75 mL/day

Interaction Checker

Enter a drug name and mineral oil

No Results

No Interactions Found

Interactions Found

Contraindicated

Serious - Use Alternative

Significant - Monitor Closely

Minor

All Interactions Sort By:

Contraindicated (0)

Serious - Use Alternative (0)

Monitor Closely (4)

beta carotene
mineral oil decreases levels of beta carotene by drug binding in GI tract. Use Caution/Monitor.
digoxin
mineral oil decreases levels of digoxin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
levonorgestrel oral/ethinylestradiol/ferrous bisglycinate
mineral oil decreases levels of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely.
vitamin D
mineral oil will decrease the level or effect of vitamin D by Other (see comment). Use Caution/Monitor. Avoid concomitant use of mineral oil and vitamin D supplements to avoid risk of decreased absorption of vitamin D. Applies to only oral administration of these agents.

Minor (22)

antithrombin alfa
mineral oil decreases levels of antithrombin alfa by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
antithrombin III
mineral oil decreases levels of antithrombin III by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
argatroban
mineral oil decreases levels of argatroban by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
bemiparin
mineral oil decreases levels of bemiparin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
bivalirudin
mineral oil decreases levels of bivalirudin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
dabigatran
mineral oil decreases levels of dabigatran by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
dalteparin
mineral oil decreases levels of dalteparin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
docusate
docusate increases levels of mineral oil by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
enoxaparin
mineral oil decreases levels of enoxaparin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
ethinylestradiol
mineral oil decreases levels of ethinylestradiol by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
fondaparinux
mineral oil decreases levels of fondaparinux by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
heparin
mineral oil decreases levels of heparin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
mestranol
mineral oil decreases levels of mestranol by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
phenindione
mineral oil decreases levels of phenindione by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
protamine
mineral oil decreases levels of protamine by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
sulfadiazine
mineral oil decreases levels of sulfadiazine by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
sulfamethoxazole
mineral oil decreases levels of sulfamethoxazole by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
sulfisoxazole
mineral oil decreases levels of sulfisoxazole by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
vitamin A
mineral oil decreases levels of vitamin A by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
vitamin E
mineral oil decreases levels of vitamin E by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
vitamin K1 (phytonadione)
mineral oil decreases levels of vitamin K1 (phytonadione) by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
warfarin
mineral oil decreases levels of warfarin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

antithrombin alfa
Minor (1)mineral oil decreases levels of antithrombin alfa by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
antithrombin III
Minor (1)mineral oil decreases levels of antithrombin III by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
argatroban
Minor (1)mineral oil decreases levels of argatroban by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
bemiparin
Minor (1)mineral oil decreases levels of bemiparin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
beta carotene
Monitor Closely (1)mineral oil decreases levels of beta carotene by drug binding in GI tract. Use Caution/Monitor.
bivalirudin
Minor (1)mineral oil decreases levels of bivalirudin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
dabigatran
Minor (1)mineral oil decreases levels of dabigatran by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
dalteparin
Minor (1)mineral oil decreases levels of dalteparin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
digoxin
Monitor Closely (1)mineral oil decreases levels of digoxin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.
docusate
Minor (1)docusate increases levels of mineral oil by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
enoxaparin
Minor (1)mineral oil decreases levels of enoxaparin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
ethinylestradiol
Minor (1)mineral oil decreases levels of ethinylestradiol by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
fondaparinux
Minor (1)mineral oil decreases levels of fondaparinux by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
heparin
Minor (1)mineral oil decreases levels of heparin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
levonorgestrel oral/ethinylestradiol/ferrous bisglycinate
Monitor Closely (1)mineral oil decreases levels of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely.
mestranol
Minor (1)mineral oil decreases levels of mestranol by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
phenindione
Minor (1)mineral oil decreases levels of phenindione by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
protamine
Minor (1)mineral oil decreases levels of protamine by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
sulfadiazine
Minor (1)mineral oil decreases levels of sulfadiazine by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
sulfamethoxazole
Minor (1)mineral oil decreases levels of sulfamethoxazole by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
sulfisoxazole
Minor (1)mineral oil decreases levels of sulfisoxazole by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
vitamin A
Minor (1)mineral oil decreases levels of vitamin A by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
vitamin D
Monitor Closely (1)mineral oil will decrease the level or effect of vitamin D by Other (see comment). Use Caution/Monitor. Avoid concomitant use of mineral oil and vitamin D supplements to avoid risk of decreased absorption of vitamin D. Applies to only oral administration of these agents.
vitamin E
Minor (1)mineral oil decreases levels of vitamin E by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
vitamin K1 (phytonadione)
Minor (1)mineral oil decreases levels of vitamin K1 (phytonadione) by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
warfarin
Minor (1)mineral oil decreases levels of warfarin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

Frequency Not Defined

Lipid pneumonitis if reclined

Incontinence of feces

Intestinal malabsorption

Impaired absorption of fat-soluble vitamins

Rectal discharge

Anal pruritus and irritation

Abdominal cramps

Nausea

Vomiting

Lipid pneumonitis with aspiration

Contraindications

Abdominal pain, nausea, vomiting, or other symptoms of appendicitis or acute surgical abdomen

Fecal impaction, intestinal obstruction or perforation, colostomy, ileostomy, ulcerative colitis, diverticulitis

Bedridden, geriatric, debilitated, or pregnant pts

Patients with esophageal or gastric retention, dysphagia, or hiatal hernia

Cautions

Conditions that interfere with swallowing or epiglottal function may increase risk of aspiration, which can result in lipid pneumonitis

Do not administer >1 week

Aspiration risk increases in the elderly

Pregnancy & Lactation

Pregnancy Category: Not recommended (no FDA risk factor assigned)

Lactation: Not known if excreted in breast milk; not recommended

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Mechanism of Action

Emollient; retards colonic absorption of water; decreases water absorption and lubricates intestine, which eases passage of stool

Pharmacokinetics

Onset of action: 6-8 hr (PO)

Distribution: Colon

Excretion: Feces

Absorption: minimal

Images

No images available for this drug.

Patient Handout

A Patient Handout is not currently available for this monograph.

Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.

[CLOSE WINDOW]